More than 50 years after the discovery of RAS family proteins, which harbor the most
common activating mutations in cancer, the US Food and Drug Administration approved the …

BACKGROUND The KRAS proto-oncogene is among the most frequently mutated genes in
cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …

For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to
therapeutic strategies based on personalized medicine owing to the complexity of designing …

Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those
targeting the MAPK pathway. Covalent inhibitors of KRAS p. G12C allele allow for direct and …

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to
clinical development—a narrative review - PMC Back to Top Skip to main content NIH NLM …

Simple Summary KRAS plays an important role in transmitting signals from growth factors on
the outside of the cell to the cell nucleus. It regulates cell proliferation, growth, and survival …

KRAS mutations are one of the most prevalent oncogenic alterations in cancer. Until
recently, drug development targeting KRAS did not convey clinical benefits to patients …

KRAS mutations are among the most common genetic alterations in lung, colorectal, and
pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit …

Abstract Purpose of Review Although the recent development of direct KRASG12C inhibitors
(G12Ci) has improved outcomes in KRAS mutant cancers, responses occur only in a fraction …